GisondiP.FacherisP.DapavoPet al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. Br J Dermatol. 2020.doi:10.1111/bjd.1915832343839
2.
HabermanR.AxelradJ.ChenAet al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. N Engl J Med. 2020.doi:10.1056/NEJMc200956732348641
3.
ShiY.WangY.ShaoCet al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. doi:10.1038/s41418-020-0530-332205856
4.
RitchieAI.SinganayagamA. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?Lancet. 2020;395(10230):1111.doi:10.1016/S0140-6736(20)30691-732220278
5.
PriceKN.FrewJW.HsiaoJL.ShiVY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82(5):e173-e175.doi:10.1016/j.jaad.2020.03.04632224277
6.
CarugnoA.RaponiF.LocatelliAGet al. No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol. 2020.doi:10.1111/jdv.1655232339362
